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2005). Thus, tumors that have circum-
vented the requirement of p63-mediated 
survival may exhibit resistance to common 
cancer treatments (Rocco et al., 2006).
In contrast, upregulation of bcl-2 
through alternative mechanisms may 
identify tumors that are resistant to the 
proapoptotic effect of these treatment 
modalities regardless of p53 family mem-
ber status. Specific bcl-2 inhibitors show 
promise as cancer therapeutics in lung and 
other cancers. Other agents hold promise 
for increasing wild-type p53 levels, thus 
abrogating the p63 survival function. It 
would be interesting to explore whether 
novel biologic treatments that abrogate 
EGFR signaling in combination with DNA 
damaging agents can also overcome 
this resistance. A recent study showed 
that the addition of an EGFR antibody to 
local radiation therapy and platinum treat-
ment markedly improved patient survival. 
Understanding the status of all p53 family 
members in HNSCC is crucial for devel-
oping more individualized combinations 
with standard DNA damaging agents and 
newer molecular therapies.
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Previous studies have demonstrated that mice lacking Cyclin D1 were refractory to mammary tumor development induced by 
the c-neu/erbB-2 oncogene, the rodent ortholog of the HER-2 receptor frequently overexpressed in human breast carcinomas. 
Two new studies in this issue of Cancer Cell provide additional evidence on this issue. Knockin mice expressing a mutant 
form of Cyclin D1 that binds to Cdk4/6 but cannot activate their catalytic activity are resistant to c-neu/erbB-2 tumorigenesis 
in spite of undergoing normal epithelial cell expansion during pregnancy. Moreover, knockdown of Cdk4 in mammary tumor 
cells abrogates tumor formation. These observations provide new compelling evidence that inhibition of Cyclin D1-Cdk4/6 
kinases might be beneficial for cancer therapy.In 2001, a seminal paper by Sicinski and 
coworkers (Yu et al., 2001) reported that 
mice lacking Cyclin D1 were refractory to 
tumorigenesis induced by MMTV-driven 
Ha-ras and c-neu/erbB-2 oncogenes. c-
neu/erbB-2 is the rodent ortholog of the 
human HER-2 receptor gene frequently 
overexpressed in human breast carci-
nomas. Indeed, HER-2 is one of the few 
oncogenes already targeted in the clinic 
by means of specific monoclonal antibod-
ies (reviewed in Hynes and Lane, 2005).
Earlier studies by Sicinski et al. (1995), 
then in the Weinberg laboratory, and by 
Fantl et al. (1995) in the Dickson labora-
tory had described that ablation of cyclin 	D1 in the germline prevented the breast 
epithelial compartment of adult female 
mice to undergo the massive prolifera-
tive changes associated with pregnancy 
despite normal levels of ovarian steroid 
hormones. In their 2001 study, Yu et al. 
(2001) concluded that c-neu/erbB-2 (and 
the Ha-ras oncogene) induced tumorigen-
esis by activating the cyclin D1 promoter. 
Hence, ablation of Cyclin D1 expression 
prevented oncogenic signaling (Figure 1). 
In contrast, other oncogenes, such as c-
myc and wnt-1, that could activate expres-
sion of other effectors, such as the related 
cyclin D2, efficiently induced mammary 
tumors in these Cyclin D1-defective mice (Yu et al., 2001). Intriguingly, c-neu/erbB-
2 and Ha-ras oncogenes induced other 
types of tumors (mainly salivary gland 
tumors) and efficiently transformed cyclin 
D1 null fibroblasts in culture (Yu et al., 
2001), indicating that the selective role of 
Cyclin D1 in mediating c-neu/erbB-2 and 
Ha-ras oncogenesis is unique to mam-
mary epithelial cells (Figure 1).
Cyclin D1 is not an obvious drugga-
ble target. Yet, one of the main biological 
activities of Cyclin D1 involves activation 
of its partners Cdk4 and Cdk6, two kinas-
es whose catalytic activity is absolutely 
dependent upon binding of any of the 
D-type Cyclins (reviewed in Malumbres cancer cell January	006	
	 p r e v i e w scancer cell January	006		Figure 1.	Therapeutic	opportunities	to	block	
ErbB-/HEr-	oncogenic	signaling
normal	mitogenic	 signaling	 (left)	and	Erb-	
(and	 presumably	 HEr-)	 signaling	 (right)	 is	
mediated	by	Cyclin	D1	or	other	D-type	Cyclins	
through	activation	of	either	Cdk4/6	kinases,	
kinase-independent	interaction	with	Cdk4/6	
and	p7Kip1,	or	interaction	with	other	targets.	
Boxes	at	the	bottom	indicate	the	main	bio-
logical	consequences	of	each	pathway.and Barbacid, 2005). Thus, the results 
of Yu et al. (2001) strongly argued that 
selective inhibitors of Cyclin D1-Cdk4/6 
kinases should have therapeutic benefit, 
at least in HER-2-positive breast cancers. 
Industry did not seem too impressed by 
these findings, and currently there is only 
one Cdk4/6-selective inhibitor undergoing 
clinical trials.
In retrospect, the emerging concept of 
cancer stem cell provides an alternative 
explanation to the results described by 
Yu et al. (2001). It is possible that c-neu/
erbB-2 and Ha-ras oncogenes preferen-
tially transform a subtype of lobuloalveolar 
breast precursor cell that is not present 
in cyclin D1-deficient mice. Instead, c-
myc and wnt-1 may target either a more 
primitive precursor that can develop in the 
absence of Cyclin D1 or a distinct precur-
sor for a related lineage. This scenario 
would imply that the failure of c-neu/erbB-
2 and Ha-ras oncogenes to induce mam-
mary tumorigenesis may not be related 
to a signaling mechanism that requires 
Cyclin D1, but to a developmental defect 
caused by targeting the cyclin D1 locus 
in the germline. If this happens to be the 
case, tampering with Cyclin D1 or its cog-
nate kinases in breast cancer patients for 
therapeutic purposes may turn out to be 
not so promising.
Possibly, these and/or similar con-
siderations may have deterred the phar-
maceutical industry from developing 
Cdk4/6-selective inhibitors. Not to worry. 
Two papers appearing in this issue of 
Cancer Cell provide renewed and more 
convincing evidence that, indeed, Cyclin 
D1-dependent Cdk4/6 kinase activity is essential for tumorigenesis mediated by 
the c-neu/erbB-2 oncogene (Landis et 
al., 2006; Yu et al., 2006). Landis et al. 
describe a new strain of gene-targeted 
mice that carries a germline mutation 
(replacement of lysine in position 112 by 
glutamic acid) within the cyclin D1 locus. 
Previous studies have shown that Cyclin 
D1K112E binds with normal affinity to Cdk4 
and Cdk6, as well as to other effectors, 
including various transcription factors. Yet, 
Cyclin D1K112E cannot activate the cata-
lytic activity of Cdk4 or Cdk6, resulting in 
the generation of kinase-defective Cyclin 
D1-Cdk4/6 complexes. These knocked-in 
mice, designated as cyclin D1KE/KE, share 
the same neurological defects (leg clasp-
ing), defective cerebellar development (in 
combination with Cyclin D2 deficiency), 
and reduced size as cyclin D1 null ani-
mals. Surprisingly, cyclin D1KE/KE mice 
display normal retinal development and 
expansion of the mammary gland during 
pregnancy. These findings provide genetic 
evidence for a significant biological role of 
Cyclin D1 that is independent of its well-
established role as the activating subunit 
of Cdk4/6 kinases.
Yet, it is possible that Cyclin D1 activity 
is not completely independent of Cdk4/6, 
at least as binding partners. Landis et al. 
(2006) report that the kinase-defective 
Cyclin D1K112E-Cdk4/6 complexes retain 
the capacity to bind the cell cycle inhibi-
tor p27Kip1. Previous studies had demon-
strated that p27Kip1 is epistatic to Cyclin 
D1, at least in the developing retina and 
in pregnancy-driven proliferation of the 
mammary gland (Geng et al., 2001; Tong 
and Pollard, 2001). Thus, it is possible that the main difference between cyclin D1−/− 
and cyclin D1KE/KE mice resides in the abil-
ity of Cyclin D1 to form trimeric complexes 
with Cdk4/6 and p27Kip1, independently of 
their kinase activity (reviewed in Sherr 
and Roberts, 1999). Interestingly, Yu et 
al. (2006) now show that transplanted 
Cdk4 null mammary glands develop nor-
mally during pregnancy, although Cdk4−/− 
females are refractory to c-neu/erbB-2 
oncogenesis. These observations suggest 
that Cyclin D1 can induce epithelial cell 
expansion during pregnancy by interact-
ing with Cdk6 alone. Whether other Cyclin 
D1 partners, mainly transcription factors, 
also play a role in Cdk4/6 kinase-indepen-
dent activities of Cyclin D1 awaits further 
studies.
Loss of Cdk4 has also been impli-
cated in resistance to tumor development 
in other tissues. For instance, ablation of 
Cdk4 renders mice resistant to carcino-
gen and Myc-induced skin tumors with-
out affecting keratinocyte proliferation 
(Rodriguez-Puebla et al., 2002; Miliani 
de Marval et al., 2004). Since Cdk4 
expression was ablated in the germline, 
it is possible that tumor resistance might 
be, at least in part, due to developmen-
tal defects. Now, Yu et al. (2006) show 
that downregulation of Cdk4 expression 
by RNAi in c-neu/erbB-2-induced mam-
mary tumor cells eliminates their onco-
genic properties when reinoculated into 
mammary fat pads. These results, taken 
together, represent the strongest genetic 
evidence generated thus far in animal 
models to support the concept that inhi-
bition of Cyclin D1-mediated Cdk4 kinase 
activity should have a therapeutic benefit 
for cancer patients.
As illustrated by Yu et al. (2006), about 
a quarter of HER-2-positive human breast 
tumors express abnormally elevated lev-
els of Cyclin D1. Are we wasting a golden 
opportunity by not developing Cdk4/6-
selective inhibitors to treat HER-2-posi-
tive breast cancers? Possibly. However, 
we must be cautious, since current ani-
mal models do not exactly recapitulate 
	 p r e v i e w sthe natural history of human tumors. First 
of all, the Cyclin D1 and Cdk4 mutations 
used in these studies were introduced 
in the germline, not in advanced tumors 
(RNAi results must be interpreted more 
cautiously, since other loci may be affect-
ed). More importantly, the etiology of 
experimental tumors differs significantly 
from that of human cancers. For instance, 
experimental mouse tumors often arise 
from tissues in which most cells carry the 
tumor-inducing mutation (MMTV-driven 
c-neu/erbB-2 expression in the papers 
discussed here). In contrast, human 
tumors, especially solid tumors, result 
from mutations in single or few cells that 
accumulate additional mutations through 
a process of clonal selection. Thus, tumor 
development in human patients is likely to 
be less dependent on any given mutated 
gene than experimental tumors. Yet, these 
considerations should not be an excuse to 
further delay testing in patients suffering 
from HER-2-positive breast tumors the 4	
During the progression of many epithelial 
cancers, including breast and colon carci-
nomas, the expression and activity of the 
tyrosine kinase Src becomes progres-
sively elevated. Src activity appears to be 
particularly important in tumor cell inva-
sion and metastasis (Frame, 2002). Thus, 
inhibition of Src inhibits tumor metastasis 
in a number of xenograft models, as well 
as in transgenic mice overexpressing 
polyoma middle T or Her2. In cell culture, 
activated Src induces the appearance of 
invasive adhesions known as podosomes 
or invadopodia, sites of local matrix degra-
dation. The pathway by which Src induces 
cell invasion through reconstituted base-
ment membrane matrices involves the 
activation of the focal adhesion kinase 
(FAK) and the stress-activated Jun kinase 
Fly Src: The Yin and Ya
suppression
The non-receptor tyrosine kinase Src is in
Vidal et al. show that loss of Drosophila C
tissue architecture. In contrast, local ina
normal tissue. This loss occurs by basal
that restrain tumor initiation.effectiveness of selective Cdk4/6 inhibi-
tors, as suggested by these new studies 
(Landis et al., 2006; Yu et al., 2006).
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tion of matrix metalloproteinases and 
other matrix-degrading proteases (Hsia 
et al., 2003). Activated Src is capable 
of inducing autonomous cell prolifera-
tion and cell transformation: viral src is a 
potent transforming gene. Yet mutations 
that activate Src are found rarely if at all 
in human cancers, and those that have 
been reported—the report has been dis-
puted—occur in advanced metastatic can-
cers (Irby et al., 1999). The reason that 
activating mutations in Src do not appear 
to initiate human cancers is unknown.
One potential explanation for the rarity 
of activating mutations in Src is the abil-
ity of normal cells to suppress the malig-
nant behavior of mutant cells within their 
midst. In cell culture, normal fibroblasts 
ng of tumor invasion an
activated by the C-terminal Src kinase Csk. I
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can suppress the transformed phenotype 
of Src-transformed fibroblasts, a phenom-
enon that does not appear to depend on 
junctional communication (Alexander 
et al., 2004). Similar tumor-suppressive 
mechanisms may operate in vivo. For 
example, normal liver tissue can induce 
the differentiation of injected hepatocarci-
noma cells, provided that the tumor cells 
are present in small groups or single cells 
(McCullough et al., 1998). Similarly, the 
formation of tumors by grafted papilloma 
cells can be suppressed by admixture with 
normal keratinocytes (Strickland et al., 
1992). Inhibition of tumor cell growth by 
adjacent normal cells has been postulated 
to represent a potent tumor suppression 
mechanism.
New light on these issues may now 
d tumor  
n a recent paper in Developmental Cell, 
ell proliferation and disorganization of 
lts in loss of cells that are adjacent to 
dings may shed light on mechanisms 
